Hanmi Pharm is dedicated to developing and providing innovative, valuable drugs to its customers. In order to pursue this goal, Hanmi is seeking out various types of collaborative opportunities, including product & pipeline in-licensing, research/development collaboration, co-promotion/co-marketing with domestic and overseas research institutes, pharmaceutical companies and biotech companies and so on.
LAPSCOVERYTM (Long Acting Protein / Peptide Discovery Platform Technology)
ORASCOVERYTM (Oral Drug Discovery Platform Technology)
PENTAMBODYTM (Penta amino acid mutated bispecific antibody)
Focusing on Core Therapeutic Areas“Creating value through innovation”
Inflammation & Fibrosis
Innovative Platform Technology
|Inflammation & Fibrosis||Metabolic Disease||Oncology/Immuno-Oncology||Rare Disease||Innovative Platform Technology|
|Extensive research on human incretin analogues to treat inflammatory and fibrotic disease||Cancer treatment through innovative platforms, TKIs, Biologics and Immuno-oncologics||Technologies to overcome rare disease.
||New modality (RNA-based therapy, Drug delivery system), COVID-19, PROTAC, AI-based platform to bring therapeutic effect|
|Co-agonists to resolute NASH, a complex disease with no approved therapies||Novel solutions for OBESITY and T2DM together with mono and combination regimens|